The Journal of pathology
Cure8 research brief
Rethinking colitis: MrgprD puts macrophages in the driver's seat†.
Research and clinical trials
Basic Science
Researchers
Clinicians
Adult patients
Inflammatory bowel disease
Why This Matters
This study highlights macrophages — immune cells already suspected in IBD — and identifies MrgprD as a molecular driver in mouse colitis models, suggesting a new potential target that might one day lead to treatments addressing immune-cell behavior rather than only broad immunosuppression.
Who Should Pay Attention
Researchers studying IBD immunology, translational scientists developing targeted therapies, pathologists interested in immune-cell markers, and clinicians following emerging mechanisms in IBD.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This paper (abstract) reports that Mas-related G protein-coupled receptor D (MrgprD) expressed in macrophages promotes colitis in a DSS mouse model by driving M1 polarization via NF-κB signaling; myeloid (not neuronal) MrgprD appears responsible, and patient genomic data analysis suggests human relevance but requires further validation.
The findings are preclinical and framed as potentially identifying MrgprD as a therapeutic target; they do not report clinical interventions or confirmed human outcomes. Consider this a hypothesis-generating basic-science study that highlights macrophage biology in IBD and may guide future translational work.
If you follow IBD research, watch for independent replication studies and work that tests whether targeting MrgprD is safe and effective in humans.
Keep In Mind
Findings are from a preclinical mouse model and genomic analyses; authors state the results need further verification. This is basic-science research that suggests a direction for future translational and clinical studies rather than immediate changes in care.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationThe Journal of pathology
AuthorsPocha K, Bräutigam K
Study typeIm, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedSep 30, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Citrullination of cathepsin H promotes NETs formation and exacerbates IBD via PI3K-Akt pathway.
The study identifies a new molecular mechanism (CTSH citrullination) that appears to drive NETs formation and worsen colitis in mice, which could point toward future therapies targeting PAD4–CTSH–NETs pathways. That...
MrgprD-mediated macrophage polarization drives chemically induced colitis in mice.
The study identifies MrgprD on colonic macrophages as a driver of pro-inflammatory macrophage polarization and worse acute colitis in mice, highlighting a potential new pathway relevant to human IBD.
IRF5 promotes the progression of ulcerative colitis by regulating macrophage polarization and Toll-like receptor signaling pathway.
The study links IRF5 to worse intestinal inflammation in UC and shows that reducing IRF5 activity lessens disease in a mouse model, suggesting IRF5 could be a future therapeutic target or biomarker.